Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Agarwal, Soumik ^a   Amin, Karishma S ^a   Jagadeesh, Shankar ^a,d   Baishay, Gokul ^b   Rao, Paruchuri G ^b   Barua, Nabin C ^b   Bhattacharya, Samir ^b,c   Banerjee, Partha P ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CSIR NORTH EAST INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^c VISVA BHARATI UNIVERSITY   (India)

^d ACell Inc   (United States)

Author keywords

DNMTs; Epigenetic silencing; Prostate cancer; RASSF1A; Tumor suppressor gene

Indexed keywords

CARBAZOLE DERIVATIVE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MAHANINE; PROTEASOME; PROTEIN KINASE B; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; CARBAZOLES; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84883151124     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-99     Document Type: Article

References (39)

1. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002, 21:5496-5503. 10.1038/sj.onc.1205602, 12154410.
2. Hodge DR, Cho E, Copeland TD, Guszczynski T, Yang E, Seth AK, Farrar WL. IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. Cancer Genomics Proteomics 2007, 4:387-398.
3. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926. 10.1016/0092-8674(92)90611-F, 1606615.
4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257. 10.1016/S0092-8674(00)81656-6, 10555141.
5. De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res 1999, 59:3855-3860.
6. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, Wang YC. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007, 55:205-213. 10.1016/j.lungcan.2006.10.022, 17140695.
7. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003, 9:4415-4422.
8. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003, 105:527-532. 10.1002/ijc.11127, 12712445.
9. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S, Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004, 164:689-699. 10.1016/S0002-9440(10)63156-2, 1602280, 14742272.
10. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179. 10.1182/blood.V97.5.1172, 11222358.
11. Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002, 33:163-171. 10.1002/mc.10033, 11870882.
12. Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, et al. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology 2011, 152:4550-4561. 10.1210/en.2011-1056, 3230051, 21990314.
13. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008, 40:741-750. 10.1038/ng.159, 18488029.
14. Bhagwat AS, Roberts RJ. Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12. J Bacteriol 1987, 169:1537-1546. 211980, 2435706.
15. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 1997, 94:4681-4685. 10.1073/pnas.94.9.4681, 20784, 9114051.
16. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994, 91:11797-11801. 10.1073/pnas.91.25.11797, 45322, 7527544.
17. Villar-Garea A, Esteller M. DNA demethylating agents and chromatin-remodelling drugs: which, how and why?. Curr Drug Metab 2003, 4:11-31.
18. Curt GA, Kelley JA, Fine RL, Huguenin PN, Roth JS, Batist G, Jenkins J, Collins JM. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). Cancer Res 1985, 45:3359-3363.
19. Boothman DA, Briggle TV, Greer S. Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol Ther 1989, 42:65-88. 10.1016/0163-7258(89)90022-3, 2657808.
20. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003, 18:665-677.
21. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem 2002, 383:907-914.
22. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002, 62:3498-3502.
23. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002, 21:6835-6840. 10.1038/sj.onc.1205814, 12360410.
24. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001, 98:7504-7509. 10.1073/pnas.131216298, 34698, 11390984.
25. Jagadeesh S, Sinha S, Pal BC, Bhattacharya S, Banerjee PP. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochem Biophys Res Commun 2007, 362:212-217. 10.1016/j.bbrc.2007.08.005, 17698033.
26. Kinney SR, Pradhan S. Regulation of expression and activity of DNA (cytosine-5) methyltransferases in mammalian cells. Prog Mol Biol Transl Sci 2011, 101:311-333.
27. Sun L, Zhao H, Xu Z, Liu Q, Liang Y, Wang L, Cai X, Zhang L, Hu L, Wang G, Zha X. Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. Cell Signal 2007, 19:2255-2263. 10.1016/j.cellsig.2007.06.014, 17716861.
28. Esteve PO, Chang Y, Samaranayake M, Upadhyay AK, Horton JR, Feehery GR, Cheng X, Pradhan S. A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability. Nat Struct Mol Biol 2011, 18:42-48. 10.1038/nsmb.1939, 3048033, 21151116.
29. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011, 21:1017-1027. 10.1101/gr.119487.110, 3129245, 21521786.
30. Sinha S, Pal BC, Jagadeesh S, Banerjee PP, Bandyopadhaya A, Bhattacharya S. Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases. Prostate 2006, 66:1257-1265. 10.1002/pros.20415, 16683271.
31. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795-4805. 10.1210/en.142.11.4795, 11606446.
32. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000, 21:2225-2235. 10.1093/carcin/21.12.2225, 11133812.
33. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005, 25:4727-4741. 10.1128/MCB.25.11.4727-4741.2005, 1140649, 15899874.
34. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319. 10.1038/77083, 10888881.
35. Banerjee PP, Banerjee S, Brown TR. Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 2001, 142:4066-4075. 10.1210/en.142.9.4066, 11517186.
36. Jagadeesh S, Kyo S, Banerjee PP. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 2006, 66:2107-2115. 10.1158/0008-5472.CAN-05-2494, 16489011.
37. Chau MN, Banerjee PP. Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. Biochem Biophys Res Commun 2008, 377:627-631. 10.1016/j.bbrc.2008.10.025, 2617746, 18930029.
38. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006, 94:1492-1495. 10.1038/sj.bjc.6603117, 2361269, 16641902.
39. Coffee B. Methylation-specific PCR. Curr Protoc Hum Genet 2009, 10:10-16.